Growth Metrics

Lineage Cell Therapeutics (LCTX) Amortizatization of Intangibles: 2010-2024

Historic Amortizatization of Intangibles for Lineage Cell Therapeutics (LCTX) over the last 13 years, with Mar 2024 value amounting to $22,000.

  • Lineage Cell Therapeutics' Amortizatization of Intangibles fell 33.33% to $22,000 in Q1 2024 from the same period last year, while for Mar 2024 it was $119,000, marking a year-over-year decrease of 17.93%. This contributed to the annual value of $22,000 for FY2024, which is 83.08% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Amortizatization of Intangibles stood at $22,000 for Q1 2024, which was down 31.25% from $32,000 recorded in Q4 2023.
  • In the past 5 years, Lineage Cell Therapeutics' Amortizatization of Intangibles ranged from a high of $498,000 in Q1 2020 and a low of $22,000 during Q1 2024.
  • Over the past 3 years, Lineage Cell Therapeutics' median Amortizatization of Intangibles value was $32,000 (recorded in 2023), while the average stood at $32,444.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Amortizatization of Intangibles plummeted by 90.09% in 2021, and later spiked by 45.45% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Amortizatization of Intangibles (Quarterly) stood at $136,000 in 2020, then plummeted by 76.47% to $32,000 in 2021, then remained steady at $32,000 in 2022, then remained steady at $32,000 in 2023, then plummeted by 33.33% to $22,000 in 2024.
  • Its Amortizatization of Intangibles stands at $22,000 for Q1 2024, versus $32,000 for Q4 2023 and $33,000 for Q3 2023.